Literature DB >> 16784412

Therapeutic options in Alzheimer's disease.

Paula I Moreira1, Xiongwei Zhu, Akihiko Nunomura, Mark A Smith, George Perry.   

Abstract

Alzheimer's disease (AD) places an enormous burden on individuals, families and society. Consequently, a tremendous effort is being devoted to the development of drugs that prevent or delay neurodegeneration. Current pharmacological treatments are based on the use of acetylcholinesterase inhibitors or memantine, a N-methyl-D-aspartate channel blocker. However, new therapeutic approaches, including those more closely targeted to the pathogenesis of the disease, are being developed. These potentially disease-modifying therapeutics include secretase inhibitors, cholesterol-lowering drugs, amyloid-beta immunotherapy, nonsteroidal anti-inflammatory drugs, hormonal modulation and the use of antioxidants. The possibility that oxidative stress is a primary event in AD indicates that antioxidant-based therapies are perhaps the most promising weapons against this devastating neurodegenerative disorder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16784412     DOI: 10.1586/14737175.6.6.897

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  12 in total

Review 1.  Oxidative damage to RNA in aging and neurodegenerative disorders.

Authors:  Akihiko Nunomura; Paula I Moreira; Rudy J Castellani; Hyoung-Gon Lee; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Neurotox Res       Date:  2012-06-06       Impact factor: 3.911

2.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 3.  Therapeutics of Neurotransmitters in Alzheimer's Disease.

Authors:  Ramesh Kandimalla; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  Frontiers in Alzheimer's disease therapeutics.

Authors:  Jeremy G Stone; Gemma Casadesus; Kasia Gustaw-Rothenberg; Sandra L Siedlak; Xinglong Wang; Xiongwei Zhu; George Perry; Rudy J Castellani; Mark A Smith
Journal:  Ther Adv Chronic Dis       Date:  2011-01-01       Impact factor: 5.091

5.  Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease.

Authors:  Piero Mannu; Salvatore Rinaldi; Vania Fontani; Alessandro Castagna
Journal:  Clin Interv Aging       Date:  2011-07-26       Impact factor: 4.458

6.  Sublethal RNA oxidation as a mechanism for neurodegenerative disease.

Authors:  Rudy J Castellani; Akihiko Nunomura; Raj K Rolston; Paula I Moreira; Atsushi Takeda; George Perry; Mark A Smith
Journal:  Int J Mol Sci       Date:  2008-05-20       Impact factor: 6.208

7.  Liuwei Dihuang (LWDH), a traditional Chinese medicinal formula, protects against β-amyloid toxicity in transgenic Caenorhabditis elegans.

Authors:  Jatinder S Sangha; Xiaoli Sun; Owen S D Wally; Kaibin Zhang; Xiuhong Ji; Zhimin Wang; Yanwen Wang; Jeffrey Zidichouski; Balakrishnan Prithiviraj; Junzeng Zhang
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

Review 8.  Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.

Authors:  Lieven D Declercq; Rik Vandenberghe; Koen Van Laere; Alfons Verbruggen; Guy Bormans
Journal:  Front Pharmacol       Date:  2016-03-31       Impact factor: 5.810

9.  Construction of AAV-rat-IL4 and Evaluation of its Modulating Effect on Aβ (1-42)-Induced Proinflammatory Cytokines in Primary Microglia and the B92 Cell Line by Quantitative PCR Assay.

Authors:  Marzieh Jamalidoust; Mehrdad Ravanshad; Mandana Namayandeh; Maryam Zare; Sadaf Asaei; Mazyar Ziyaeyan
Journal:  Jundishapur J Microbiol       Date:  2016-03-05       Impact factor: 0.747

10.  Scorpion Venom Heat-Resistant Peptide Protects Transgenic Caenorhabditis elegans from β-Amyloid Toxicity.

Authors:  Xiao-Gang Zhang; Xi Wang; Ting-Ting Zhou; Xue-Fei Wu; Yan Peng; Wan-Qin Zhang; Shao Li; Jie Zhao
Journal:  Front Pharmacol       Date:  2016-07-26       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.